Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
Pipeline News and Updates
Picture

Prescribe Right Pharmaceutical Pipeline Update for September 26

9/26/2018

 
Thirty-one citations were added to our knowledgebase bringing the total to 809. Each citation is accessible from the single drug look-up monograph via a URL link. There are now 612 investigational drugs in the Knowledgebase.

Two Updates on products with PDUFA Dates and/or Priority Designations
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended approval of Lilly’s galcanezumab. The FDA has Fast-Tracked the drug with a review date next week, September 30, 2018.

J&J announced that in a 4-week, 346 patient, Phase III trial, esketamine nasal spray added to a new anti-depressant did not improve Montgomery-Asberg Depression Rating Scale (MADRS) total score compared to monotherapy with a new antidepressant in patients with treatment-resistant depression. No PDUFA date but the drug has a Breakthrough Therapy Priority Designation.

Five additional updates:
  • A pooled analysis of 3,492 patients in 8 trials involving baricitinib (Lilly, Incyte) found mortality, cardiovascular events and serious infection rates similar to placebo. Brand name: Olumiant.
  • Astellas announced topline results from a 52-week, Phase III trial in which roxadustat achieved a hemoglobin response rate in the first 24 weeks and hemoglobin change from baseline at Weeks 28 to 52 compared to placebo in CKD patients with anemia. 
  • Novo Nordisk announced that in a Phase III trial, daily oral semaglutide lowered HbA1c 1.8% with 14mg, 1.4% with 7mg and 0.7% with 3 mg compared to a 1.3% reduction with weekly dulaglutide 0.75 mg in Japanese type 2 diabetic patients. The effect on weight with semaglutide was a 1.9 kg loss with 14 mg, 1 kg loss with 7mg and a 0.1 kg weight gain with 3 mg compared to a 1.1 kg gain with dulaglutide.
  • In a 390-patient, open label trial involving dengue naive US adults, use of a compressed vaccination schedule (0-2-6 months) was comparable to the standard scheduled (0-6-12 months) given with or without concomitant yellow fever vaccine. Patients that received the compressed schedule were 73.4% seropositive for ≥3 serotypes and 50% seropositive for all four serotypes compared to 82.4% and 42.6% for the standard schedule.
  • In a 37-month, 1,147 patient, Phase III trial, treatment with Novartis’ buparlisib plus Astra Zeneca’s fulvestrant (FDA approval date 11/15/2017) was no better than fulvestrant monotherapy in overall survival of the total population or patients with PIK3CA-mutant ctDNA.

You can access up-to-date information on all drugs in the late stages of development with the 
Prescribe Right Pharmaceutical Pipeline Tracker.

Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.